NASDAQ:CPRX

Catalyst Pharmaceuticals Competitors

$4.44
-0.03 (-0.67 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.30
Now: $4.44
$4.47
50-Day Range
$3.50
MA: $4.17
$4.73
52-Week Range
$2.88
Now: $4.44
$5.19
Volume1.16 million shs
Average Volume1.74 million shs
Market Capitalization$460.98 million
P/E Ratio6.63
Dividend YieldN/A
Beta1.53

Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) Vs. FGEN, MORF, PAND, FPRX, CYTK, and AMRX

Should you be buying CPRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Catalyst Pharmaceuticals, including FibroGen (FGEN), Morphic (MORF), Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), Cytokinetics (CYTK), and Amneal Pharmaceuticals (AMRX).

Catalyst Pharmaceuticals (NASDAQ:CPRX) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Insider & Institutional Ownership

64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 11.7% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 3.4% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Catalyst Pharmaceuticals and FibroGen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalyst Pharmaceuticals00403.00
FibroGen15202.13

Catalyst Pharmaceuticals currently has a consensus target price of $7.6250, suggesting a potential upside of 71.73%. FibroGen has a consensus target price of $45.8333, suggesting a potential upside of 130.20%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Catalyst Pharmaceuticals.

Volatility & Risk

Catalyst Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Profitability

This table compares Catalyst Pharmaceuticals and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalyst Pharmaceuticals60.48%35.04%29.73%
FibroGen-191.78%-48.19%-27.72%

Earnings and Valuation

This table compares Catalyst Pharmaceuticals and FibroGen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80
FibroGen$256.58 million7.10$-76,970,000.00($0.89)-22.37

Catalyst Pharmaceuticals has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Catalyst Pharmaceuticals beats FibroGen on 9 of the 14 factors compared between the two stocks.

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Profitability

This table compares Catalyst Pharmaceuticals and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalyst Pharmaceuticals60.48%35.04%29.73%
MorphicN/A-36.62%-20.69%

Analyst Recommendations

This is a summary of current ratings and target prices for Catalyst Pharmaceuticals and Morphic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalyst Pharmaceuticals00403.00
Morphic00203.00

Catalyst Pharmaceuticals currently has a consensus target price of $7.6250, suggesting a potential upside of 71.73%. Morphic has a consensus target price of $63.3333, suggesting a potential upside of 14.98%. Given Catalyst Pharmaceuticals' higher possible upside, research analysts clearly believe Catalyst Pharmaceuticals is more favorable than Morphic.

Earnings and Valuation

This table compares Catalyst Pharmaceuticals and Morphic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80
Morphic$16.98 million105.26$-43,330,000.00($2.69)-20.48

Catalyst Pharmaceuticals has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 11.7% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 39.5% of Morphic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Catalyst Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Morphic on 11 of the 13 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Pandion Therapeutics and Catalyst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
Catalyst Pharmaceuticals60.48%35.04%29.73%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pandion Therapeutics and Catalyst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
Catalyst Pharmaceuticals00403.00

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Catalyst Pharmaceuticals has a consensus price target of $7.6250, suggesting a potential upside of 71.73%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Pandion Therapeutics.

Valuation & Earnings

This table compares Pandion Therapeutics and Catalyst Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80

Catalyst Pharmaceuticals has higher revenue and earnings than Pandion Therapeutics.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are held by institutional investors. Comparatively, 64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. 11.7% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats Pandion Therapeutics on 10 of the 11 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Five Prime Therapeutics and Catalyst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Catalyst Pharmaceuticals60.48%35.04%29.73%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Five Prime Therapeutics and Catalyst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Catalyst Pharmaceuticals00403.00

Five Prime Therapeutics currently has a consensus price target of $30.7143, suggesting a potential downside of 19.17%. Catalyst Pharmaceuticals has a consensus price target of $7.6250, suggesting a potential upside of 71.73%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Five Prime Therapeutics.

Valuation & Earnings

This table compares Five Prime Therapeutics and Catalyst Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million119.01$-137,200,000.00($3.92)-9.69
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80

Catalyst Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by company insiders. Comparatively, 11.7% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Five Prime Therapeutics on 11 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Cytokinetics and Catalyst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
Catalyst Pharmaceuticals60.48%35.04%29.73%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cytokinetics and Catalyst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
Catalyst Pharmaceuticals00403.00

Cytokinetics currently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Catalyst Pharmaceuticals has a consensus price target of $7.6250, suggesting a potential upside of 71.73%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Cytokinetics.

Valuation & Earnings

This table compares Cytokinetics and Catalyst Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80

Catalyst Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.1% of Cytokinetics shares are held by institutional investors. Comparatively, 64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. 6.4% of Cytokinetics shares are held by company insiders. Comparatively, 11.7% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Cytokinetics on 11 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Amneal Pharmaceuticals and Catalyst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amneal Pharmaceuticals3.30%42.02%3.82%
Catalyst Pharmaceuticals60.48%35.04%29.73%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Amneal Pharmaceuticals and Catalyst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amneal Pharmaceuticals01502.83
Catalyst Pharmaceuticals00403.00

Amneal Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 18.85%. Catalyst Pharmaceuticals has a consensus price target of $7.6250, suggesting a potential upside of 71.73%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Valuation & Earnings

This table compares Amneal Pharmaceuticals and Catalyst Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$1.63 billion1.09$-361,920,000.00$0.2721.81
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. 26.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 11.7% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Amneal Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Catalyst Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FibroGen logo
FGEN
FibroGen
1.8$19.91-3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34News Coverage
Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00Gap Up
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
Gap Down
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Gap Down
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.